TQB-2934

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameTQB-2934
Drug Alias NameTQB2934TQB-2934
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-BCMA
TargetsT cell surface glycoprotein CD3B-cell maturation protein
Therapy Area/IndicationsAmyloidosisMultiple MyelomaImmunoglobulin Light-chain Amyloidosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co LtdNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAmyloidosisMultiple MyelomaImmunoglobulin Light-chain Amyloidosis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A